MedTrace Logo

Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease

NCT01393678 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2011-07-13

No results posted yet for this study

Summary

The drug in this study is combined product of biphenyl dimethyl dicarboxylate (DDB) and garlic oil. This components showed synergistic enhancing effects in previous tests. In phase 2 test, 6 cap three times a day dosage (2cap T.I.D) is better than other dosage. Based on above, this study is phase 3 test to prove efficacy and safety of PENNEL.

Conditions

Interventions

DRUG

NISSEL

Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap

DRUG

PENNEL

Biphenyl Dimethyl Dicarboxylate 25mg \& garlic oil 50mg ............. 1cap

Sponsors & Collaborators

  • PharmaKing

    lead INDUSTRY

Principal Investigators

  • Minho Lee, MD.PhD · Hanyang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-11-30
Primary Completion
1998-03-31
Completion
1998-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01393678 on ClinicalTrials.gov